Related Symbol
avatar
@Ethancollins 2 days ago

Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition

Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition

Boston Scientific is making a major move in the debt market, pricing $3 billion in US dollar-denominated senior notes alongside another €4.25 billion in euro-denominated notes.

The bigger story is where that money is going. The company plans to use the proceeds, along with cash and additional borrowing, to help finance its proposed acquisition of Penumbra . The deal was valued at approximately $14.5 billion when announced.

What caught my attention is the scale of the financing. Boston Scientific is taking on a substantial funding commitment to expand its medical technology business, and the acquisition could strengthen its position in areas such as vascular and neurovascular treatments.

But there’s a risk investors shouldn’t overlook. More borrowing means additional interest costs, and the company will need to make sure the acquisition delivers enough long-term value to justify the investment.

Personally, I see the strategic opportunity, but execution and debt management will be just as important as the deal itself.

Do you think the Penumbra acquisition will be worth the financial commitment for Boston Scientific, or is the company taking on too much debt?

@DamnRay 2 days ago

I'm bullish on the acquisition fs. Boston Scientific is buying access to an attractive growth market, and Penumbra could strengthen its competitive position significantly. The debt is substantial, but I'd rather see a strategic acquisition than sitting on cash with no growth plan.

@bennettOlivia7 2 days ago

I get that, and the deal does make sense strategically. But I wouldn't automatically call taking on debt better than sitting on cash. $14.5 billion is a lot to justify, even for a business with good growth prospects